ABIOMED (ABMD) : Juncture Wealth Strategies scooped up 215 additional shares in ABIOMED during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 14, 2016. The investment management firm now holds a total of 10,988 shares of ABIOMED which is valued at $1,290,760.ABIOMED makes up approximately 0.90% of Juncture Wealth Strategies’s portfolio.
Other Hedge Funds, Including , Balasa Dinverno Foltz added ABMD to its portfolio by purchasing 3,914 company shares during the most recent quarter which is valued at $459,778. ABIOMED makes up approx 0.08% of Balasa Dinverno Foltz’s portfolio.Cutler Group Lp reduced its stake in ABMD by selling 8,503 shares or 78.79% in the most recent quarter. The Hedge Fund company now holds 2,289 shares of ABMD which is valued at $268,969. ABIOMED makes up approx 0.02% of Cutler Group Lp’s portfolio.Weaver C. Barksdale Associates reduced its stake in ABMD by selling 103 shares or 86.55% in the most recent quarter. The Hedge Fund company now holds 16 shares of ABMD which is valued at $1,880.
ABIOMED opened for trading at $117.91 and hit $118.26 on the upside on Monday, eventually ending the session at $117.47, with a gain of 0.28% or 0.33 points. The heightened volatility saw the trading volume jump to 3,43,322 shares. Company has a market cap of $5,020 M.
On the company’s financial health, ABIOMED reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.18. The company had revenue of $94.00 million for the quarter, compared to analysts expectations of $90.46 million. The company’s revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.24 EPS.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.